A provocative question now circulating in dermatology coverage asks whether PASI 75 — the endpoint long treated as the benchmark of successful psoriasis treatment — still deserves its status as the gold standard.

The question itself signals a shift underway in how clinicians, regulators, and trial designers think about measuring therapeutic success in plaque psoriasis. PASI, the Psoriasis Area and Severity Index, quantifies erythema, induration, and desquamation across body surface areas. A PASI 75 response means a 75% or greater reduction from baseline severity. For years, hitting that threshold defined a "responder" in randomized controlled trials and shaped regulatory approvals, label claims, and payer coverage decisions.

The case for revisiting that benchmark is straightforward. As the question's framing implies, the treatments available today have moved the ceiling of achievable outcomes. When the field's most effective therapies routinely deliver responses well beyond 75% clearance, a bar set at PASI 75 may no longer discriminate between agents, may understate clinically meaningful differences in efficacy, and may set treatment goals too low for patients who could realistically reach clear or almost-clear skin.

That logic has consequences across the clinical pathway. In trial design, an endpoint that most investigational agents surpass provides little statistical power to distinguish candidates. In the clinic, a treatment goal anchored to PASI 75 can leave patients with visible, symptomatic disease that a higher standard would classify as an inadequate response warranting therapy escalation.

The debate is not purely academic. Treatment targets influence payers' prior authorization criteria, step-therapy protocols, and the documentation dermatologists must submit to secure continued coverage of biologic agents. If the field formally abandons PASI 75 as the reference point, reimbursement frameworks that still cite it would come under pressure to update their thresholds accordingly.

For dermatologists, the practical question is what replaces it. Any successor standard must balance higher expectations against real-world heterogeneity — differences in disease severity at baseline, comorbidities, prior treatment failures, and patient preferences all shape what constitutes an adequate response for a given individual. A single numeric cutoff, whatever its value, captures only part of that picture.

Patients, too, weigh in on this recalibration. What registers as success in a trial statistician's spreadsheet and what registers as success to a patient living with residual plaques are not always the same thing. Any redefinition of the gold standard will need to reconcile trial-level endpoints with individual-level treatment satisfaction.

The question now on the table — whether PASI 75 remains the gold standard — frames a moment of transition for the specialty. How guideline bodies, regulators, and payers answer it in the coming cycle will shape both the endpoints of the next generation of psoriasis trials and the everyday treatment goals dermatologists set with their patients.